A retrospective review of California poison control system data of sibutramine exposures Sibutramine exposures

Clinical Toxicology

Volumn 47, Issue 8, 2009, Pages 814-817

  Minns, Alicia Bethany ^a   Ebrahimi, Shirley ^b   Te, Lena ^b   Ly, Binh ^a   Clark, Richard F ^a   Cantrell, F Lee ^c  

^a University of California   (United States)

^b UNIVERSITY OF SAN FRANCISCO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Management; Overdose; Pediatric; Poison control centers; Poisoning management

Indexed keywords

SIBUTRAMINE;

ADOLESCENT; ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; COMA; CONTROL SYSTEM; CONTROLLED STUDY; DATA BASE; DIZZINESS; DROWSINESS; DRUG OVERDOSE; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFANT; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIOSIS; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POISON CENTER; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; STROKE; TACHYCARDIA; THORAX PAIN; TREMOR; UNITED STATES; VERTIGO; VOMITING;

ADOLESCENT; ADULT; APPETITE DEPRESSANTS; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CYCLOBUTANES; DATABASES AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; OVERDOSE; POISON CONTROL CENTERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350350311     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650903206844     Document Type: Article

References (16)

1. Meridia(R) [package insert]. North Chicago, IL: Abbott; 2007.
2. Lee J, Teoh T, Lee T. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res 2008; 64:107-109.
3. Esposito P, Rampino T, Gregorini M. Severe symptomatic hyponatremia during sibutramine therapy: a case report. Am J Kidney Dis 2008; 52:137-139.
4. Perrio MJ, Wilton LV, Shakir SAW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity 2007; 15:2712-2722.
5. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2007; 9:378-387.
6. Bronstein AC, Spyker DA, Cantilena LR, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol 2007; 48:815-917.
7. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26(14):1027-1048.
8. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure; a metaanalysis of controlled trials. Obes Res 2003; 11(9):1116-1123.
9. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16:5-11.
10. Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial J Cardiovasc Pharmacol 2008; 52(5):393-402.
11. Daniels SR, Long B, Styne D. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, doubleblind, placebo-controlled study. Pediatrics 2007; 120(1):e147-e157.
12. Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry 2002; 159(10):1793-1794.
13. Dogangun B, Bolat N, Rustamov I, Kayaalp L. Sibutramine-induced psychotic episode in an adolescent. J Psychosom Res 2008; 65:505-506.
14. Taflinsji T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000; 157(12):2057-2058.
15. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapineassociated weight gain. Am J Psychiatry 2005; 162(5):954-962.
16. Hoffman, R. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol 2007; 45:943-945.